Nature Communications (Feb 2021)
Pancreatic glycoprotein 2 is a first line of defense for mucosal protection in intestinal inflammation
- Yosuke Kurashima,
- Takaaki Kigoshi,
- Sayuri Murasaki,
- Fujimi Arai,
- Kaoru Shimada,
- Natsumi Seki,
- Yun-Gi Kim,
- Koji Hase,
- Hiroshi Ohno,
- Kazuya Kawano,
- Hiroshi Ashida,
- Toshihiko Suzuki,
- Masako Morimoto,
- Yukari Saito,
- Ai Sasou,
- Yuki Goda,
- Yoshikazu Yuki,
- Yutaka Inagaki,
- Hideki Iijima,
- Wataru Suda,
- Masahira Hattori,
- Hiroshi Kiyono
Affiliations
- Yosuke Kurashima
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- Takaaki Kigoshi
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- Sayuri Murasaki
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- Fujimi Arai
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- Kaoru Shimada
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- Natsumi Seki
- Division of Biochemistry, Graduate School of Pharmacological Science, Keio University
- Yun-Gi Kim
- Research Center for Drug Discovery, Faculty of Pharmacy, Keio University
- Koji Hase
- International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo
- Hiroshi Ohno
- Laboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences
- Kazuya Kawano
- Laboratory for Intestinal Ecosystem, RIKEN Center for Integrative Medical Sciences
- Hiroshi Ashida
- Department of Bacterial Infection and Host Response, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
- Toshihiko Suzuki
- Department of Bacterial Infection and Host Response, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
- Masako Morimoto
- Department of Innovative Medicine, Graduate School of Medicine, Chiba University
- Yukari Saito
- Department of Innovative Medicine, Graduate School of Medicine, Chiba University
- Ai Sasou
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- Yuki Goda
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- Yoshikazu Yuki
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- Yutaka Inagaki
- Center for Matrix Biology and Medicine, Graduate School of Medicine, Tokai University
- Hideki Iijima
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University
- Wataru Suda
- Laboratory for Microbiome Sciences, RIKEN Center for Integrative Medical Sciences
- Masahira Hattori
- Laboratory for Microbiome Sciences, RIKEN Center for Integrative Medical Sciences
- Hiroshi Kiyono
- Department of Mucosal Immunology, The University of Tokyo Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo
- DOI
- https://doi.org/10.1038/s41467-021-21277-2
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 17
Abstract
Glycoprotein-2 (GP-2) can protect the intestinal epithelial barrier from bacteria and is associated with protection against Crohn’s disease. Here, the authors show pancreatic GP-2 is the source of the intestine’s luminal GP-2 that binds bacteria and prevents them from attaching to the epithelium, also limiting pathology in a DSS colitis mouse model.
